Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Clinical Oncology

• Publication date

  2002-09-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1200/JCO.2002.05.102PMID 12228200
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Measurement of regional cerebral blood flow and oxygen utilisation in patients with cerebral tumours using 15O and positron emission tomography: Analytical techniques and preliminary results

  2004cited by this paper
• Zinc ligand-disrupted recombinant human Endostatin: Potent inhibition of tumor growth, safety and pharmacokinetic profile

  2004cited by this paper
• Phase I study of recombinant human endostatin in patients with advanced solid tumors.

  2002cited by this paper
• Interaction of endostatin with integrins implicated in angiogenesis.

  2001cited by this paper
• Antiangiogenesis signals by endostatin.

  2001cited by this paper
• Endostatin Binds Tropomyosin

  2001cited by this paper
• Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

  2001cited by this paper
• Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.

  2001cited by this paper
• Cell surface glypicans are low-affinity endostatin receptors.

  2001cited by this paper
• Molecular addresses in blood vessels as targets for therapy.

  2001cited by this paper
• Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.

  2000cited by this paper
• Anatomy of SUV. Standardized uptake value.

  2000cited by this paper
• Measuring tumor blood flow with H(2)(15)O: practical considerations.

  2000cited by this paper
• Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis.

  2000cited by this paper
• Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase.

  2000cited by this paper
• Anatomy of SUV

  2000cited by this paper
• Cloning, Expression, andin VitroActivity of Human Endostatin

  1999cited by this paper
• Cloning, expression, and in vitro activity of human endostatin.

  1999cited by this paper
• Endostatin Induces Endothelial Cell Apoptosis*

  1999cited by this paper
• Endostatin inhibits VEGF‐induced endothelial cell migration and tumor growth independently of zinc binding

  1999cited by this paper
• Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications.

  1999cited by this paper
• Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.

  1999cited by this paper
• Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors.

  1999cited by this paper
• Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display.

  1998cited by this paper
• Simple and Patlak models for myocardial blood flow measurements with nitrogen-13-ammonia and PET in humans.

  1998cited by this paper
• Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

  1997cited by this paper
• Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

  1997cited by this paper
• Angiostatin induces and sustains dormancy of human primary tumors in mice

  1996cited by this paper
• Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia.

  1996cited by this paper
• Patterns and Emerging Mechanisms Review of the Angiogenic Switch during Tumorigenesis

  1996cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Barriers to drug delivery in solid tumors.

  1994cited by this paper
• Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method.

  1992cited by this paper
• Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation

  1992cited by this paper
• Low oxygen extraction fraction in tumours measured with the oxygen-15 steady state technique: effect of tissue heterogeneity.

  1992cited by this paper
• Sensitivity of measurements of regional brain activation with oxygen-15-water and PET to time of stimulation and period of image reconstruction.

  1991cited by this paper
• Fitting piecewise linear regression functions to biological responses.

  1989cited by this paper
• The proof and measurement of association between two things. By C. Spearman, 1904.

  1987cited by this paper
• Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma.

  1984cited by this paper
• In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas

  1983cited by this paper
• Robust Locally Weighted Regression and Smoothing Scatterplots

  1979cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper
• Fibers in Cultured Human Endothelial Cells with Concomitant Loss of Focal Adhesions and Actin Stress Endostatin-induced Modulation of Plasminogen Activation Updated Version Cited Articles Citing Articles E-mail Alerts Endostatin-induced Modulation of Plasminogen Activation with Concomitant Loss of F

  year unknowncited by this paper

• Molecular magnetic resonance imaging of Alpha-v-Beta-3 integrin expression in tumors with ultrasound microbubbles.

  2021cites this paper
• A comparison study of dual-energy spectral CT and 18F-FDG PET/CT in primary tumors and lymph nodes of lung cancer.

  2021cites this paper
• Conventional to Early Phase Standardized Uptake Value Ratio on 18F FDG PET/CT Could Reflect Prognosis in Patients with Non-small Cell Lung Cancer

  2021cites this paper
• DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma

  2020cites this paper
• VEGF-A INHIBITION AS A TREATMENT MODALITY FOR KAPOSI SARCOMA

  2019cites this paper
• Monitoring tumor response to the vascular disrupting agent CKD-516 in a rabbit VX2 intramuscular tumor model using PET/MRI: Simultaneous evaluation of vascular and metabolic parameters

  2018cites this paper
• Monitoring of tumor vascular normalization: the key points from basic research to clinical application

  2018cites this paper
• 2 Resistance to Apoptosis in Cancer Therapy

  2017cites this paper
• Gene-based antiangiogenic applications for corneal neovascularization.

  2017cites this paper
• Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.

  2016cites this paper
• Quantification and clinical applicability of novel oncology PET imaging biomarkers

  2015cites this paper
• Radiopharmaceuticals as probes to characterize tumour tissue

  2015cites this paper
• Phase I Trials Today

  2015cites this paper
• Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine?

  2015cites this paper
• Deciphering the anti-angiogenic effect of endostatin/cyclophosphamide to normalize tumor micrangium through notch signaling pathway in colon cancer

  2015cites this paper
• Imaging as a pharmacodynamic and response biomarker in cancer

  2014cites this paper
• Radionuclides for Imaging and Therapy in Oncology

  2014cites this paper
• PET imaging to monitor cancer therapy.

  2014cites this paper
• Randomised controlled trial of the effects of fish oil emulsion in total parenteral nutrition upon tumour vascularity in patients with hepatic colorectal metastases

  2014cites this paper
• Anti-Tumor Effect of a Novel Soluble Recombinant Human Endostatin: Administered as a Single Agent or in Combination with Chemotherapy Agents in Mouse Tumor Models

  2014cites this paper
• Multiparametric Monitoring of Early Response to Antiangiogenic Therapy: A Sequential Perfusion CT and PET/CT Study in a Rabbit VX2 Tumor Model

  2014cites this paper
• PET imaging of neovascularization with (68)Ga-3PRGD2 for assessing tumor early response to Endostar antiangiogenic therapy.

  2014cites this paper
• Positron emission tomography to assess hypoxia and perfusion in lung cancer.

  2014cites this paper
• Radiopharmaceuticals for Imaging in Oncology with Special Emphasis on Positron-Emitting Agents

  2013cites this paper
• Modeling Tumor Vasculature: Molecular, Cellular, and Tissue Level Aspects and Implications

  2012cites this paper
• Vascular Biomarkers and Imaging Studies

  2012cites this paper
• Blood Perfusion in Solid Tumor with “Normalized” Microvasculature

  2012cites this paper
• Systems Biology of Pancreatic Cancer: The Role of Tumor-Microenvironment Communication in Development, Progression and Therapy Resistance

  2012cites this paper
• Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials

  2012cites this paper
• Molecular Imaging of Tumor Angiogenesis

  2012cites this paper
• Aspects of perfusion quantification using contrast-enhanced ultrasound within the clinical context of colorectal liver metastases

  2012cites this paper
• Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?

  2012cites this paper
• The effect of intravitreal bevacizumab (Avastin) injection on retinal blood flow velocity in patients with choroidal neovascularization

  2012cites this paper
• Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels.

  2012cites this paper
• Applications of Positron Emission Tomography in the Development of Molecular Targeted Cancer Therapeutics

  2012cites this paper
• PET imaging of early response to the tyrosine kinase inhibitor ZD4190

  2011cites this paper
• A furin/MMP-14 proteolytic cascade generates Vasculostatin-40 from extracellular BAI1: Implications for angiogenesis and tumorigenesis

  2011cites this paper
• Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET

  2011cites this paper
• Simulation of tumor microvasculature and microenvironment response to anti-angiogenic treatment by angiostatin and endostatin

  2011cites this paper
• Molecular imaging in cancer treatment

  2011cites this paper
• Comparison of the antiangiogenic activity of modified RGDRGD-endostatin to endostatin delivered by gene transfer in vivo rabbit neovascularization model

  2011cites this paper
• Opportunities and pitfalls of cancer imaging in clinical trials

  2011cites this paper
• Inhibitory effect of radiotherapy combined with weekly recombinant human endostatin on the human pulmonary adenocarcinoma A549 xenografts in nude mice.

  2011cites this paper
• identication of differentially expressed genes in a renal cell carinoma tumor model after endostatin-treatment

  2011cites this paper
• Anti-tumor effects of pEgr-1-endostatin-TNF-α recombinant plasmid expression induced by ionizing radiation.

  2011influential citation
• Multiplexed PET probes for imaging breast cancer early response to VEGF₁₂₁/rGel treatment.

  2011cites this paper
• Angiogenesis and Lung Cancer

  2011cites this paper
• PET/CT Imaging

  2011cites this paper
• Unexpected properties of endostatin-producing mouse BCR-ABL-transformed cells.

  2011cites this paper
• Lister Vaccine Strain of Vaccinia Virus Armed with the Endostatin–Angiostatin Fusion Gene: An Oncolytic Virus Superior to dl1520 (ONYX-015) for Human Head and Neck Cancer

  2011cites this paper
• Multifunctional MR Imaging Assessments: A Look into the Future

  2010cites this paper
• Radionuclide imaging of perfusion and hypoxia

  2010cites this paper
• Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.

  2010cites this paper
• Targeted therapies in renal cell cancer: recent developments in imaging

  2010cites this paper
• Imaging angiogenesis of genitourinary tumors

  2010cites this paper
• Multiparametric imaging of tumor response to therapy.

  2010cites this paper
• Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer

  2010cites this paper
• Quantitative Parametric Perfusion Images Using 15O-Labeled Water and a Clinical PET/CT Scanner: Test–Retest Variability in Lung Cancer

  2010cites this paper
• Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?

  2010cites this paper
• The use of endostatin in the treatment of solid tumors

  2009cites this paper
• Angiogenic Signalling Pathways

  2009cites this paper
• The use of endostatin in the treatment of solid tumors.

  2009cites this paper
• Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs

  2009cites this paper
• Tumor Blood Flow Measured by Perfusion Computed Tomography and 15O-Labeled Water Positron Emission Tomography: A Comparison Study

  2009cites this paper
• Tumor stroma derived biomarkers in cancer

  2009cites this paper
• Unraveling the mysteries of endostatin

  2009cites this paper
• Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice

  2009cites this paper
• Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET

  2009influential citation
• Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy.

  2009cites this paper
• Hypothesis: primary antiangiogenic method proposed to treat early stage breast cancer

  2009cites this paper
• Molecular imaging in clinical trials

  2009cites this paper
• Anti-angiogenic cancer therapy updates.

  2009cites this paper
• Use of H2(15)O-PET and DCE-MRI to measure tumor blood flow.

  2008cites this paper
• Imaging of Tumor Angiogenesis and Antiangiogenesis

  2008cites this paper
• Magnetic Resonance Imaging ^ Measured Blood Flow Change after AntiangiogenicTherapy with PTK 787 / ZK 222584 Correlates with Clinical Outcome inMetastatic Renal Cell Carcinoma

  2008cites this paper
• Application of PET/CT in the development of novel anticancer drugs.

  2008cites this paper
• Endpoints for the Determination of Efficacy of Antiangiogenic Agents in Clinical Trials

  2008cites this paper
• Molecular Imaging of Targets and Therapeutics in Tumour Angiogenesis

  2008cites this paper
• Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow

  2008cites this paper
• Inhibitors of Tumor Angiogenesis

  2008cites this paper
• Surrogates for Clinical Development

  2008cites this paper
• Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium

  2008cites this paper
• Clinical use of therapies targeting tumor vasculature and stroma.

  2008cites this paper
• Warburg revisited: imaging tumour blood flow and metabolism

  2008cites this paper
• Reproducibility of Tumor Perfusion Measurements Using 15O-Labeled Water and PET

  2008cites this paper
• Role of Imaging in Drug Development

  2008cites this paper
• Imaging and cancer: A review

  2008cites this paper
• Clinical biomarkers of angiogenesis inhibition

  2008cites this paper
• The Role of Imaging in the Clinical Development of Antiangiogenic Agents

  2008cites this paper
• Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer

  2008cites this paper
• Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma

  2008cites this paper
• CHAPTER 15 – Inhibitors of tumor angiogenesis

  2008cites this paper
• Bioactivity, pharmacokinetics, and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin

  2008cites this paper
• Chapter 23 – Imaging and Cancer

  2008cites this paper
• Imaging the Effect of Anti-Angiogenic Tumor Therapy in Clinical Studies

  2008cites this paper
• Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment

  2008cites this paper
• Non-invasive assessment of tumor neovasculature: techniques and clinical applications

  2008cites this paper
• How to Define Treatment Success or Failure if Tumors Do Not Shrink

  2008cites this paper
• Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice.

  2007cites this paper
• Positron Emission Tomography Imaging of Blood Flow and Hypoxia in Tumors

  2007cites this paper